Re-registration: ANC >= ,/mm^
ANC ? /mm
Must have measurable MM
Prior treatment with MM-
Measurable (>mm x mm) contrast enhancing disease.
ANC must be ? /mm;
ANC >/mm.
ANC >/= /mm, Cohort  (PTCL): ANC >/= /mm
ANC* ? /mm (? . x ^/L)
Adequate bone marrow function: white blood cells (WBCs) ? ,/mm, absolute neutrophil count (ANC) ? ,/mm, hemoglobin ?  g/dL, and platelets ? ,/mm
Adequate hematology without ongoing transfusional support (hemoglobin >  g/dL, ANC > , per mm, platelets > , per mm).
Absolute neutrophil count (ANC) >= /mm^; (ANC > /mm^ may be considered in special circumstances such as benign cyclical neutropenia as judged by the investigator and in discussion with the sponsor)
Absolute neutrophil count (ANC) >= . K/cu mm; for subjects with ANC < . K/cu mm due to significant marrow involvement by MCL, ANC must be > . K/cu mm
Adequate hematologic function (Platelets ? ,/mm, lymphocytes ? ,/mm, neutrophils ? /mm, hemoglobin ?  g/dl).
Adequate hematological function, defined as ANC ? ,/mm, Hb ? . g/dL, and platelet count ? ,/mm.
ANC ?,/mm^ (?.x^/L)
Evidence of MM disease progression any time prior to enrollment; progression from smoldering/asymptomatic MM to symptomatic MM is not exclusionary
An absolute neutrophil count (ANC) > ,/mm^ (patients who have bone marrow infiltration by MCL are eligible if their ANC is >= /mm^ [growth factor allowed]; these patients should be discussed with either the principal investigator [PI] or Co-PI of the study for final approval)
Platelets >= ,/mm^ or >= ,/mm^ in the setting of marrow involvement by disease or splenomegaly due to disease
Relapsed/refractory MCL: Absolute neutrophil count (ANC) >= /mm^; (patients who have bone marrow infiltration by MCL are eligible if their ANC is >= /mm^ [growth factor allowed]; these patients should be discussed with either the principal investigator [PI] or Co-PI of the study for final approval)
Hematopoietic Function: WBC ? ,/mm; ANC ? /mm; Hemoglobin ?  g/dL; Platelet count ? ,/mm; Coagulation: INR ? ..
Adequate hematologic function (Platelets ? ,/mm, lymphocytes ? , mm, neutrophils ? /mm, hemoglobin ? . g/dl).
Adequate hematologic reserve obtained ?  weeks prior to entry: leukocytes ? , mm^; absolute neutrophil count ?  mm^; platelets ? , mm^
Adequate hematology without ongoing transfusional support (hemoglobin >  g/dL, ANC > , per mm, platelets > , per mm).
ANC > /mm, plt count > ,/mm
Has MM positive for t(;).
Adequate hematology without ongoing transfusional support (hemoglobin >  g/dL, ANC ? , per mm, platelets > , per mm)
Patients must have adequate hematologic reserve as evidenced by absolute neutrophil count (ANC) >= /mm^ and platelets >= ,/mm^
ANC ?,/mm^ (?. x ^/L)
Marrow: Peripheral blood leukocyte count (WBC) < /mm, absolute neutrophil count ? /mm, platelets < /mm, or hemoglobin <  gm/dL
MM diagnostic criteria (all  required);
ABC count ? ,/mm
Marrow: Peripheral blood leukocyte count (WBC) < /mm, absolute neutrophils count ? /mm, platelets < /mm, or hemoglobin <  gm/dL.
ANC: for patients with lymphoma ?/mm (?.  ^/L), for patients with advanced solid tumors ?,/mm (?.  ^/L),
ANC ? , / mm
Marrow: Peripheral blood leukocyte count (WBC) < /mm, absolute neutrophil count ? /mm, platelets < /mm, or hemoglobin <  gm/dL
Marrow: Hemoglobin >= . g/dL, absolute neutrophil count (ANC) >=,/mm, and platelets >=,/mm.
Platelet count > ,/mm^; (patients who have bone marrow infiltration by MCL are eligible if their ANC is >= /mm^ [growth factor not allowed] or their platelet level is >= ,/mm^)
Absolute neutrophil count (ANC) > ,/mm^; (patients who have bone marrow infiltration by MCL are eligible if their ANC is >= /mm^ [growth factor not allowed] or their platelet level is >= ,/mm^)
PHASE II: Alternatively, with less BM involvement, an ANC >= /mm^, and platelet count >= , mm^ is required
Hb concentration <. mmol/L (<. g/dL); WBC <x/L (/mm); platelets <x/L (x/mm).
Neutrophiles <,/mm
ANC >= ,/mm^
Absolute neutrophil count (ANC) > ,/mm^; (patients who have bone marrow infiltration by MCL are eligible if their ANC is /mm^ [growth factor allowed] or their platelet level is equal to or > than ,/mm^)
ANC ?/mm
Patients should have adequate bone marrow function defined as a peripheral WBC >,/mm with an ANC >/mm and a platelet count >,/mm.
Adequate hematologic function including ANC ? /mm, Hemoglobin ?  g/dL (transfusion is permitted), and platelets ? ,/mm.
Patients with nodal disease limited to micrometastases (pNMi, > . mm and =<  mm) or isolated tumor cells (pNi+ < . mm)
ANC of >/mm
ANC of >/mm independent of G-CSF
ANC of >/mm independent of G-CSF
MM diagnostic criteria (all  required):
Smoldering MM.
Smoldering MM.
Has a single lesion with a maximum size of ?  mm with ?  mm of capsular contact as confirmed by MR imaging,
Have had at least one prior episode of fever and neutropenia (ANC < /mm^ or expected to fall below < /mm^) during doxorubicin and cyclophosphamide (AC)
No metastatic sites >=  mm
ANC ? /mm
At least  mm of tumor on biopsy (can have multiple cores to comprise  mm)
ANC ?  mm, platelets ? ,/mm, hemoglobin ?  g/dL,
